2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide(SALTDATA: 1.74HCl 0.19H2O)
- $65 - $320
- Product name: 2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide(SALTDATA: 1.74HCl 0.19H2O)
- CAS: 1152853-30-9
- MF: C6H10N4O
- MW: 154.17
- EINECS:
- MDL Number:MFCD11054006
- Synonyms:2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide(SALTDATA: 1.74HCl 0.19H2O);2-(4-Amino-1H-pyrazol-1-yl)-N-methylacetamide monohydrobromide;2-(4-aminopyrazol-1-yl)-N-methylacetamide
3 prices
Selected condition:
Brand
- AK Scientific
- ChemBridge Corporation
- TRC
Package
- 50mg
- 250mg
- 500mg
- ManufacturerAK Scientific
- Product number9556AC
- Product description2-(4-Amino-1H-pyrazol-1-yl)-N-methylacetamidehydrochloride
- Packaging500mg
- Price$320
- Updated2021-12-16
- Buy
- ManufacturerChemBridge Corporation
- Product numberBB-4087929
- Product description2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide 95%
- Packaging250mg
- Price$84
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberA632270
- Product description2-(4-Amino-1H-pyrazol-1-yl)-N-methylacetamideDihydrochloride
- Packaging50mg
- Price$65
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 9556AC | 2-(4-Amino-1H-pyrazol-1-yl)-N-methylacetamidehydrochloride | 500mg | $320 | 2021-12-16 | Buy |
ChemBridge Corporation | BB-4087929 | 2-(4-amino-1H-pyrazol-1-yl)-N-methylacetamide 95% | 250mg | $84 | 2021-12-16 | Buy |
TRC | A632270 | 2-(4-Amino-1H-pyrazol-1-yl)-N-methylacetamideDihydrochloride | 50mg | $65 | 2021-12-16 | Buy |
Properties
Boiling point :444.3±25.0 °C(Predicted)
Density :1.35±0.1 g/cm3(Predicted)
pka :15.12±0.46(Predicted)
Density :1.35±0.1 g/cm3(Predicted)
pka :15.12±0.46(Predicted)
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|